Xencor, Inc.
$12.8
▲
2.23%
2026-04-21 10:21:01
www.xencor.com
NGM: XNCR
Explore Xencor, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$941.6 M
Current Price
$12.8
52W High / Low
$18.69 / $6.92
Stock P/E
—
Book Value
$8.84
Dividend Yield
—
ROCE
-22.77%
ROE
-14.07%
Face Value
—
EPS
$-1.24
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
260
Beta
0.99
Debt / Equity
29.54
Current Ratio
6.25
Quick Ratio
6.25
Forward P/E
-4.08
Price / Sales
7.25
Enterprise Value
$550.88 M
EV / EBITDA
-3.3
EV / Revenue
4.39
Rating
Strong Buy
Target Price
$28.42
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | IN8bio, Inc. | $1.5 | — | $14.77 M | — | -68.2% | -92.49% | $5.82 / $1.17 | $2.82 |
| 2. | Amicus Therapeutics, Inc. | $14.46 | — | $4.54 B | — | 4.84% | -11.58% | $14.48 / $5.51 | $0.88 |
| 3. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
| 4. | DiaMedica Therapeutics Inc. | $6.56 | — | $369.1 M | — | -61.16% | -67.68% | $10.42 / $3.28 | $1.04 |
| 5. | Alaunos Therapeutics, Inc. | $2.84 | — | $6.71 M | — | -233.25% | -1.98% | $6.2 / $1.67 | $1.27 |
| 6. | GRI Bio, Inc. | $2.51 | — | $3.68 M | — | -198.85% | -2.38% | $80.36 / $2.1 | $12.07 |
| 7. | Tenax Therapeutics, Inc. | $14.1 | — | $247.99 M | — | -58.09% | -55.64% | $18.38 / $4.63 | $2.29 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 28.24 M | 21 M | 43.61 M | 32.73 M | 70.02 M |
| Operating Profit | -53.63 M | -47.52 M | -33.17 M | -43.18 M | 4.05 M |
| Net Profit | -6.65 M | -6.03 M | -30.82 M | -48.42 M | -53.48 M |
| EPS in Rs | -0.09 | -0.08 | -0.42 | -0.66 | -0.73 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 125.58 M | 110.49 M | 174.62 M | 164.58 M |
| Operating Profit | -177.5 M | -178.41 M | -132.36 M | -82.47 M |
| Net Profit | -91.92 M | -232.62 M | -133.13 M | -55.18 M |
| EPS in Rs | -1.25 | -3.17 | -1.82 | -0.75 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 875.5 M | 951.95 M | 965.13 M | 846.27 M |
| Total Liabilities | 239.91 M | 277.92 M | 303.05 M | 118.77 M |
| Equity | 635.59 M | 677.61 M | 661.75 M | 727.5 M |
| Current Assets | 599.82 M | 577.6 M | 635.6 M | 675.34 M |
| Current Liabilities | 95.91 M | 87.43 M | 73.92 M | 63.84 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -135.12 M | -202.19 M | -77.93 M | 24.48 M |
| Investing CF | 139.99 M | -7.87 M | -111.06 M | -119.72 M |
| Financing CF | 8.23 M | 197.15 M | 189.22 M | 5.7 M |
| Free CF | -138.27 M | -211.7 M | -99.18 M | -18.92 M |
| Capex | -3.15 M | -9.51 M | -21.25 M | -43.4 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 13.65% | -36.72% | 6.1% | — |
| Earnings Growth % | 60.48% | -74.73% | -141.27% | — |
| Profit Margin % | -73.2% | -210.53% | -76.24% | -33.53% |
| Operating Margin % | -141.35% | -161.47% | -75.8% | -50.11% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -37.58% | -168.49% | -58.39% | -27.77% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.